VIBRAMYCIN (doxycycline calcium) by Pfizer is mechanism of action mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. Approved for the following infections: rocky mountain spotted fever, typhus fever, the typhus group and 9 more indications. First approved in 1974.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
VIBRAMYCIN (doxycycline calcium) is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, exhibiting bacteriostatic activity against Gram-positive and Gram-negative bacteria. It is indicated for rickettsial infections (Rocky Mountain spotted fever, Q fever, typhus), sexually transmitted infections, malaria prophylaxis in travelers, and other bacterial and parasitic infections. The drug has been approved since 1974 and is available as an oral suspension formulation.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential downsizing of brand-focused teams and shift toward generic management or portfolio optimization.
Mechanism of Action Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is…
Worked on VIBRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VIBRAMYCIN as an internal Pfizer employee offers stability in a well-established infectious disease franchise, but limited growth upside as LOE approaches; roles are increasingly focused on defending market share against generics and optimizing operational efficiency. Career progression is slower; candidates should target transition roles in pipeline products, specialty care, or generic management to build future marketability.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo